199 related articles for article (PubMed ID: 23721553)
1. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era.
Evens AM; Choquet S; Kroll-Desrosiers AR; Jagadeesh D; Smith SM; Morschhauser F; Leblond V; Roy R; Barton B; Gordon LI; Gandhi MK; Dierickx D; Schiff D; Habermann TM; Trappe R
Am J Transplant; 2013 Jun; 13(6):1512-22. PubMed ID: 23721553
[TBL] [Abstract][Full Text] [Related]
2. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
3. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
[TBL] [Abstract][Full Text] [Related]
4. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
[TBL] [Abstract][Full Text] [Related]
5. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.
Cavaliere R; Petroni G; Lopes MB; Schiff D;
Cancer; 2010 Feb; 116(4):863-70. PubMed ID: 20052713
[TBL] [Abstract][Full Text] [Related]
7. Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres.
Santarsieri A; Rudge JF; Amin I; Gelson W; Parmar J; Pettit S; Sharkey L; Uttenthal BJ; Follows GA
Br J Haematol; 2022 May; 197(3):310-319. PubMed ID: 35235680
[TBL] [Abstract][Full Text] [Related]
8. A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.
Lake W; Chang JE; Kennedy T; Morgan A; Salamat S; Başkaya MK
Neurosurgery; 2013 Jun; 72(6):960-70; discussion 970. PubMed ID: 23685504
[TBL] [Abstract][Full Text] [Related]
9. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
[TBL] [Abstract][Full Text] [Related]
10. Post-transplantation lymphoproliferative disorders (PTLD) localized in the central nervous system: report from an international survey on PTLD.
Khedmat H; Taheri S
Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):235-42. PubMed ID: 23538344
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series.
Seçkin D; Barete S; Euvrard S; Francès C; Kanitakis J; Geusau A; Del Marmol V; Harwood CA; Proby CM; Ali I; Güleç AT; Durukan E; Lebbé C; Alaibac M; Laffitte E; Cooper S; Bouwes Bavinck JN; Murphy GM; Ferrándiz C; Mørk C; Cetkovská P; Kempf W; Hofbauer GF
Am J Transplant; 2013 Aug; 13(8):2146-53. PubMed ID: 23718915
[TBL] [Abstract][Full Text] [Related]
12. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
Burns DM; Clesham K; Hodgson YA; Fredrick L; Haughton J; Lannon M; Hussein H; Shin JS; Hollows RJ; Robinson L; Byrne C; McNamara C; Vydianath B; Lennard AL; Fields P; Johnson R; Wright J; Fox CP; Cwynarski K; Chaganti S
Transplantation; 2020 Dec; 104(12):2582-2590. PubMed ID: 33104308
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Romero S; Montoro J; Guinot M; Almenar L; Andreu R; Balaguer A; Beneyto I; Espí J; Gómez-Codina J; Iacoboni G; Jarque I; López-Andújar R; Mayordomo-Aranda E; Montalar J; Pastor A; Pastor M; Piñana JL; Rojas-Ferrer N; Sánchez-Lázaro I; Sandoval J; Sanz G; Sanz MÁ; Solé A; Sanz J
Leuk Lymphoma; 2019 Jan; 60(1):142-150. PubMed ID: 29966464
[TBL] [Abstract][Full Text] [Related]
14. Tumor Infiltrating Lymphocytes Predict Survival in Solid Organ Transplant Recipients With Monomorphic Post-transplant Lymphoproliferative Disorders.
Stubbins RJ; Lam R; Zhu J; Ghosh S; Mabilangan C; Kuruvilla J; Goswami RS; Lai R; Preiksaitis JK; Jain MD; Peters AC
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):744-752. PubMed ID: 35717340
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients.
Reams BD; McAdams HP; Howell DN; Steele MP; Davis RD; Palmer SM
Chest; 2003 Oct; 124(4):1242-9. PubMed ID: 14555552
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma.
Ginat DT; Purakal A; Pytel P
J Neurooncol; 2015 Nov; 125(2):297-305. PubMed ID: 26341369
[TBL] [Abstract][Full Text] [Related]
17. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.
Dugan JP; Haverkos BM; Villagomez L; Martin LK; Lustberg M; Patton J; Martin M; Huang Y; Nuovo G; Yan F; Cavaliere R; Fingeroth J; Kenney SC; Ambinder RF; Lozanski G; Porcu P; Caligiuri MA; Baiocchi RA
Clin Cancer Res; 2018 Jul; 24(14):3273-3281. PubMed ID: 29632007
[No Abstract] [Full Text] [Related]
18. Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.
Füreder A; Kropshofer G; Benesch M; Dworzak M; Greil S; Huber WD; Hubmann H; Lawitschka A; Mann G; Michel-Behnke I; Müller-Sacherer T; Pichler H; Simonitsch-Klupp I; Schwinger W; Szepfalusi Z; Crazzolara R; Attarbaschi A;
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1375. PubMed ID: 33755341
[TBL] [Abstract][Full Text] [Related]
19. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
[TBL] [Abstract][Full Text] [Related]
20. Impact of the posttransplant lymphoproliferative disorder subtype on survival.
Koff JL; Li JX; Zhang X; Switchenko JM; Flowers CR; Waller EK
Cancer; 2018 Jun; 124(11):2327-2336. PubMed ID: 29579330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
